Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase (OTCQB: TLTFF) closed a combined financing totaling CAN$2.66 million on April 10, 2026, including a CAN$1.665M non-brokered unit offering and a CAN$1.0M revolving line of credit.
Units issued: 6,404,700 at CAN$0.26 (one share + one warrant, 5-year CAN$0.36 exercise). Insider subscriptions totaled 937,400 units. Proceeds will fund a Phase II NMIBC CIS study, GLP toxicology for Rutherrin, and working capital.
Theralase (OTCQB: TLTFF) reports a new mechanism explaining how Ruvidar inactivates herpes simplex virus 1 (HSV-1). Researchers measured zeta potential changes showing Ruvidar binds and neutralizes the virus surface charge, blocking cell entry.
In vitro, Ruvidar at ~1.3 µM produced up to an 8 log reduction (99.999999%) in infectious virions. Preclinical and clinical development for a topical HSV-1 treatment is slated to commence in 2026.
Theralase (OTCQB: TLTFF, TSXV: TLT) closed a non-brokered private placement of 4,230,770 Units at CAD 0.26 per Unit for gross proceeds of CAD 1.1 million on March 10, 2026. Each Unit includes one common share and one warrant exercisable at CAD 0.36 for five years.
Proceeds will fund the ongoing Phase II NMIBC clinical study, working capital and general corporate purposes. Securities are subject to a four-month-and-one-day hold expiring July 11, 2026, and final TSXV acceptance.
Theralase (OTCQB: TLTFF) reported preclinical data (March 9, 2026) showing X-Ray-activated Rutherrin significantly increased destruction of muscle invasive bladder cancer (MIBC) versus radiation alone. In mice, tumour sites had ~4x Rutherrin uptake; Rutherrin + radiation produced complete tumour clearance at day 35 versus persistent disease or humane endpoints with radiation alone.
The company plans a Phase 0/I/II adaptive clinical study of radiation-activated Rutherrin for MIBC, subject to regulatory approval.
Theralase (OTCQB: TLTFF) reported in vitro data showing that combining light-activated Ruvidar with recombinant human interferon alpha-2b produced substantially greater bladder cancer cell kill than interferon alone. Key finding: the combination yielded 50–65% higher total cell kill versus no Ruvidar across tested doses.
The results showed dose-dependent cytotoxicity for both agents and support a planned combinational clinical study for BCG-unresponsive NMIBC CIS patients.
Theralase (OTCQB: TLTFF) announced interim Phase II bladder cancer data will be presented at the 2026 European Association of Urology Congress (EAU26) in London, March 13-16, 2026. Enrollment in the BCG-unresponsive NMIBC CIS Study II is complete.
Results show early signals: 2 of 3 patients achieved complete response, 2 of 5 maintained response ≥15 months, and 1 of 5 showed ≥3 years duration after a single treatment. The company plans rolling regulatory submissions to Health Canada and the FDA beginning 3Q2026, with approval targeted in 2027.
Theralase (OTCQB: TLTFF) announced interim Phase II clinical data for light-activated Ruvidar (TLD-1433) in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ (NMIBC CIS), selected for oral presentation at EAU26 in London, March 13–16, 2026.
Enrollment in the international, multicenter Study II is complete. Interim findings show 2 of 3 patients achieved complete response, 2 of 5 maintained response ≥15 months, and 1 of 5 showed ≥3 years' response after one treatment. A rolling submission to Health Canada and FDA is planned to start in 3Q2026, with regulatory approval expected in 2027.
Theralase (OTCQB: TLTFF) announced interim Phase II clinical data for light-activated Ruvidar (TLD-1433) in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ (NMIBC CIS), accepted for interactive poster presentation at the 2026 AUA Annual Meeting (May 15-18, 2026).
The interim dataset highlights 78 patients who completed enrollment, with select responses: 2/3 complete responses in a subset, 2/5 maintaining response ≥15 months, and 1/5 showing ≥3-year duration after a single treatment. Rolling regulatory submissions to Health Canada and the FDA are expected to begin in 3Q2026, with approvals targeted in 2027.
Theralase (OTCQB: TLTFF) reported interim Phase II bladder cancer results, enrolling 90 patients with 78 completions and 12 pending. Primary endpoint: CR 64.4% (56/87), total response 73.6% at any time. Duration analysis (450 days) shows CR 40.4% (19/47). Safety: 100% (78/78) evaluated as unrelated or unlikely related to study drug/device. Company plans 2026 data compilation for submissions to Health Canada and FDA with targeted regulatory approval in 2027.
Theralase (TSXV: TLT) (OTCQB: TLTFF) completed enrollment and treatment of 90 patients in a multi-center Phase II registrational study for BCG-unresponsive NMIBC CIS using light-activated Ruvidar.
The study’s primary endpoint is efficacy; secondary is duration of response and tertiary is safety. Company expects study completion and preparation of Health Canada and FDA submissions in 2026.